The term Grants applies to the provision of funding for actual goods and services given for the purpose of supporting healthcare, scientific research, or education. This is in response to an unsolicited request from a healthcare organisation, or an individual involved with the provision of healthcare, and must be provided without any implied or actual benefit in return for Daiichi Sankyo UK.
Grants to individuals are prohibited.
Daiichi Sankyo UK are committed to supporting projects, initiatives, and concepts which enhance patient care or benefit the NHS and maintain sustainable, high-quality care for patients.
This could include, but is not limited to:
All grants are provided on the basis of application merit and are not allocated on the basis of any perceived or expected financial material benefit to the Daiichi Sankyo UK organisation. All grants are considered on a first-come-first-serve basis and allocation of funding may be influenced by availability of budgets at the time of the application.
As part of a national programme established with NHS England, Daiichi Sankyo UK is committing financial and operational support as appropriate towards initiatives and projects which seek to reduce national, regional, and local detect, protect, and perfect (DPP) gaps in the atrial fibrillation (AF)-related stroke prevention therapy area, as well as the broader holistic cardiovascular disease management pathway.
As part of this wider programme, Daiichi Sankyo UK is accepting grant applications for projects and initiatives which seek to optimise patient care across the AF-related stroke prevention. To submit grant applications for DPP projects and initiatives, please follow the process towards the bottom of this page.
Daiichi Sankyo UK receives many requests for funding and may not be able to support all applications. Whilst all requests are considered, each request may not be successful.
All funding approval is at the discretion of Daiichi Sankyo UK Ltd and request for funding should be within one of our focus disease areas:
Daiichi Sankyo UK Ltd considers the following factors when evaluating which activities to support.
Please note that applications are not guaranteed even if all criteria are met.
If support is provided through a grant this must be acknowledged and apparent on any materials associated with the activity e.g., educational items or materials used. In line with the requirements of the ABPI Code of Practice for the Pharmaceutical Industry, details of grant funding provided by Daiichi Sankyo UK will be publicly disclosed annually on the ABPI central website platform for disclosure in the UK.
As a UK-based pharmaceutical company, Daiichi Sankyo UK adheres to the ABPI Code of Practice, including the requirements for annual disclosure of transfer of value for the corresponding period.
Details of each grant (transfer of value) must be publicly disclosed annually, giving in each case the financial amount or value and the name of the recipient institution, organisation, or association. Companies are also encouraged to ask recipients to make such funding public. Where applicable, fees and expenses should be disclosed separately. Disclosure must be carried out in accordance with Clauses 28 and 29. Further information on public disclosures of transfer value from Daiichi Sankyo UK can be found on the Disclosure UK portal: https://search.disclosureuk.org.uk/
To apply for a grant from Daiichi Sankyo UK please download and complete the appropriate form and the anti-bribery questionnaire Please note both fully completed forms are required in order for an application to be accepted and processed.
Please do not use the below forms to report adverse events.
For activities not covered by a DSUK Grant, please see the Q&A document below.
The relevant application forms are available below
Once completed, please email the forms to Grantsanddonations@daiichi-sankyo.co.uk
Side effects (adverse events) should be reported. The documents for some medicines also display an inverted black triangle symbol indicating that they are subject to additional monitoring to support the quick identification of new safety information.
If you are a patient and experience any side effects while taking a Daiichi Sankyo product, please talk to your doctor, pharmacist, or nurse. You can also report side effects directly to the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help build the knowledge regarding the safety of the medicine.
If you are a health professional, adverse event reporting forms and information can be found at www.mhra.gov.uk/yellowcard (or search for MHRA Yellow Card in Google Play or Apple App store). Adverse events should also be reported to Daiichi Sankyo on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk
DSC/23/0237 - August 2023
